Eric Secemsky, MD, from Beth Israel Deaconess Medical Center and Harvard Medical School, says a lack of hands-on training and reimbursement challenges are hindering the adoption of IVUS.
The FDA-approved technology developed by HeartFlow can predict a patient's long-term risk of target vessel failure as well as more invasive treatments performed inside a cath lab.